I find this part of the Release, very interesting indeed!
Renascor (as well as ‘at least’ one other industry participant) has now opposed the pending patent application to protect and preserve its flexibility to use these processing procedures (or similar), should it wish to do so.
DC would simply say, ‘as well as one other industry participant’, if it was just Dornfer Anzaplan. However, he didn’t, he added the term ’at least’ which is unnecessary and that’s not DC's typical writing style unless there are more players backing his brave stance to do what is right on behalf of the integrity of the manufacturing industry in this country.
Therefore, I think we may assume that there are now registered and unregistered concerns? If that’s the case, the heat could be on EGR's management and their lawyers will have their work cut out for themselves in the foreseeable future. Also, I suspect that the pressure will keep mounting as the word gets out.
Understandably, while Dorfner Anzaplan and RNU are out there batting for the underdog, some industry players may not have been aware of this patent application or in a position to be drawn into what really is an immaterial matter, yet still have the same concerns about the ‘overly broad processing procedures of this patent’, that has somehow got through after being initially quashed by IP Australia.
As RNU mentioned in the Release, irrespective of the outcome, RNU will not be adversely impacted.
On the other hand, in the light of this announcement, this is potentially far more devastating for our western wannabes, especially if they are getting bombarded by other industry leaders then, it does raise the question as to what EGR’s ASX-listing obligations are and whether this needs to be addressed to appease their shareholder’s concerns. After all, for years of building a brand and messaging around having some kind of IP advantage, and then to be told, actually you have nothing special to offer, will be a set back and questions their management practices.
Suggested questions EGR SH's might like to ask AS are: Apart from Dorfner Anzaplan and RNU, are there any other ‘unregistered’ concerns from industry that you are aware of? Do we have a legitimate case? Does this affect our ability to commission the plant and conduct general business activities going forward? Is a patent conditional to unlocking government funds and securing offtake partners? Why were we knocked back for the HFfree trademark application? Can we see the 'adverse report' and are we likely to pursue it further?
So many questions for EGR to address but I’m sure our social media curmudgeon can try his best to obfuscate an answer for us on behalf of his interests!
All IMO, DYOR, GLTA(patient)H
Expand
(20min delay)
